Prostatic adenocarcinoma is cancer that starts in the gland-forming cells of the prostate. It accounts for the vast majority of prostate cancers, making it the most common type by far. About 13.2% of men will be diagnosed with prostate cancer at some point in their lifetime, and nearly all of those diagnoses are specifically adenocarcinoma. If you’ve seen this term on a biopsy report or heard it from a doctor, it refers to the standard form of prostate cancer rather than a rare or unusual subtype.
Where It Starts
The prostate is a walnut-sized gland that sits below the bladder and produces some of the fluid in semen. Its inner lining contains secretory epithelial cells, which are the cells responsible for making that fluid. Prostatic adenocarcinoma begins when these specific cells start growing in an uncontrolled way. The prefix “adeno” means gland, and “carcinoma” means cancer of the lining cells, so the name literally translates to “glandular cancer.”
Under a microscope, these cancer cells look distinctly different from normal prostate tissue. They crowd together in abnormal patterns and lose the outer layer of supportive cells (called basal cells) that normally surrounds healthy prostate glands. That missing layer is one of the key features pathologists look for when confirming a diagnosis. The cancer cells also have enlarged nuclei and can invade the space around nearby nerves, which is another hallmark finding on biopsy.
Symptoms by Stage
Early-stage prostatic adenocarcinoma often produces no symptoms at all. Many cases are discovered through routine screening before a man notices anything wrong. When early symptoms do appear, they tend to involve urination: needing to go more frequently, difficulty starting the stream, waking up at night to urinate, or blood in the urine or semen. These symptoms overlap heavily with benign prostate enlargement, which is why they can be easy to dismiss.
Advanced disease looks quite different. When the cancer has spread beyond the prostate, symptoms can include bone pain (especially in the back, hips, or pelvis), unexplained weight loss, persistent fatigue, weakness in the arms or legs, erectile dysfunction, and loss of bladder control. Bone pain in particular is a red flag because prostate cancer has a strong tendency to spread to the skeleton.
How It’s Diagnosed
Diagnosis typically begins with a PSA blood test, which measures a protein produced by the prostate. There’s no single cutoff that definitively separates normal from abnormal. Generally, a level above 4.0 ng/mL prompts further investigation, though some doctors use a lower threshold of 2.5 ng/mL for younger men and a higher one for older men, since PSA naturally rises with age. An elevated PSA doesn’t mean cancer is present. Infections, benign enlargement, and even recent physical activity can raise the number.
If PSA results or a physical exam raise concern, a biopsy is the next step. A pathologist examines tissue samples under a microscope, looking for the characteristic crowded glandular patterns, missing basal cell layers, and enlarged nuclei that define adenocarcinoma. Imaging studies like MRI may be used before or after biopsy to map the extent of the tumor.
Grading: The Gleason Score
Once adenocarcinoma is confirmed, the pathologist assigns a grade that reflects how aggressive the cancer cells appear. This system is called the Gleason score. The pathologist identifies the two most common growth patterns in the biopsy, each rated from 3 to 5 (grades 1 and 2 are no longer used), and adds them together. A score of 3+3=6 is the lowest possible, representing slow-growing cells that are unlikely to spread.
These scores are also translated into Grade Groups from 1 to 5, which are easier to interpret:
- Grade Group 1 (Gleason 6): Least aggressive. Cells grow slowly and are very unlikely to spread.
- Grade Group 2 (Gleason 3+4=7): Still relatively favorable, but contains some more abnormal-looking cells.
- Grade Group 3 (Gleason 4+3=7): Moderately aggressive. The dominant pattern is more disorganized.
- Grade Group 4 (Gleason 8): Aggressive cancer cells with highly irregular patterns.
- Grade Group 5 (Gleason 9-10): Most aggressive. Cells barely resemble normal gland tissue.
The grade matters enormously for treatment decisions. A Grade Group 1 cancer may never need active treatment, while Grade Group 4 or 5 typically calls for prompt intervention.
Staging: How Far It Has Spread
Staging describes the physical extent of the cancer using the TNM system. The T category focuses on the primary tumor in the prostate:
- T1: The tumor can’t be felt on exam or seen on imaging. It was found incidentally during a procedure or biopsy prompted by elevated PSA.
- T2: The tumor can be felt during a rectal exam or seen on imaging but is still confined to the prostate. T2a means it’s in half or less of one side; T2c means it involves both sides.
- T3: The cancer has grown through the prostate wall and may have reached the seminal vesicles.
- T4: The cancer has invaded nearby structures like the bladder, rectum, or pelvic wall.
Doctors also assess whether cancer has reached nearby lymph nodes (N category) or distant organs like bones (M category). Together, the grade and stage create the full picture that guides treatment.
Treatment Options
Treatment depends heavily on the cancer’s grade, stage, and how quickly it appears to be growing.
Active Surveillance
For low-grade, early-stage disease (typically Grade Group 1), active surveillance is a common and well-supported approach. Rather than treating immediately, your doctor monitors the cancer with regular PSA tests, exams, and periodic biopsies. The goal is to avoid the side effects of treatment unless the cancer shows signs of becoming more aggressive. A modeling study comparing active surveillance to immediate surgery projected that men on surveillance lived an average of 6.4 more years free from treatment and its side effects. The trade-off was small: the 20-year risk of dying from prostate cancer was 2.8% with surveillance compared to 1.6% with surgery, a difference that translated to roughly 1.8 months of additional life expectancy with immediate surgery.
Surgery and Radiation
For cancer that’s still confined to the prostate but is higher-grade, surgical removal of the prostate (radical prostatectomy) or radiation therapy are the primary options. Both aim to eliminate the cancer entirely. Side effects can include urinary incontinence and erectile dysfunction, though outcomes have improved with modern surgical techniques. Radiation can be delivered externally or through small radioactive seeds implanted directly into the prostate.
Hormone Therapy
Prostate cancer cells rely on male hormones called androgens to grow. Androgens bind to receptors on prostate cells and signal them to multiply. Hormone therapy works by either reducing the body’s production of androgens or blocking the cancer cells from using them. This approach is commonly used for cancer that has spread beyond the prostate or that has returned after initial treatment. It can also be combined with radiation for higher-risk localized disease. Hormone therapy is highly effective at slowing growth, but it comes with its own side effects, including hot flashes, loss of libido, fatigue, and reduced bone density over time.
PSA Screening Guidelines
Screening recommendations vary by organization, but the common thread is shared decision-making. The U.S. Preventive Services Task Force recommends that men aged 55 to 69 discuss the pros and cons of PSA screening with their doctor and make an individual choice based on their values. For men 70 and older, the Task Force recommends against routine screening. The American Urological Association similarly targets the 55 to 69 age range and suggests screening no more often than every two years to reduce unnecessary biopsies.
For men at higher risk, conversations about screening may start earlier. The American Cancer Society recommends discussing screening beginning at age 50 for average-risk men, and earlier for Black men and those with a father or brother diagnosed before age 65. Black men have a notably higher incidence of prostate cancer and are more likely to be diagnosed with aggressive forms.
Outlook and Survival
The prognosis for prostatic adenocarcinoma is generally very favorable when caught early. Localized and regional prostate cancers, meaning the disease hasn’t spread to distant organs, have high long-term survival rates. Even among all stages combined, prostate cancer has one of the better survival profiles of any cancer. The picture changes for cancer that has already spread to bones or distant lymph nodes at the time of diagnosis, where survival rates are significantly lower but treatment can still extend life for years. About 333,830 new cases are expected in the U.S. in 2026 alone, making it one of the most commonly diagnosed cancers in men.